Unknown EARLY_PHASE1 INTERVENTIONAL 7-arm NCT03931668

Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers

A Single Site, Randomized, Double-blind, Placebo-controlled, Incremental Phase I Clinical Trial: to Evaluate the Tolerance, PK and PD Effects of TPN-672 Maleate in Chinese Healthy Volunteers After Single Dose Administration.

Sponsor: Jiangsu Kanion Pharmaceutical Co.

Conditions PHA1A

Interventions TPN-672

Updated 6 times since 2019 Last updated: Dec 20, 2019 Started: Apr 17, 2019 Primary completion: Oct 17, 2020 Completion: Dec 17, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates PHA1A and is currently ongoing. Jiangsu Kanion Pharmaceutical Co. leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting EARLY_PHASE1
Jan 2020 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

▶ Show 1 earlier version

May 2019 — Jan 2020 [monthly]

Recruiting EARLY_PHASE1

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Kanion Pharmaceutical Co.
Shanghai Mental Health Center

Data source: Shanghai Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China